FATE
Fate Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About FATE
Fate Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing programmed cellular immunotherapies for the treatment of cancer diseases
Pharmaceutical
04/27/2007
10/01/2013
NASDAQ Stock Exchange
181
12-31
Common stock
12278 Scripps Summit Drive, San Diego, California 92131
--
Fate Therapeutics, Inc., merged in Delaware on April 27, 2007, is a clinical staging biopharmaceutical company dedicated to the exploration and development of adult stem cell therapy modulators for the treatment of rare diseases, including some malignant hematological diseases, lysosomal storage disorder and muscular dystrophy. Some of the new approaches used by Fate take existing therapeutic models, including small molecules and therapeutic proteins, and target good biological mechanisms to enhance the efficacy of adult stem cells.
Company Financials
EPS
FATE has released its 2025 Q3 earnings. EPS was reported at -0.27, versus the expected -0.28, beating expectations. The chart below visualizes how FATE has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
FATE has released its 2025 Q3 earnings report, with revenue of 1.74M, reflecting a YoY change of -43.36%, and net profit of -32.25M, showing a YoY change of 32.36%. The Sankey diagram below clearly presents FATE's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
